1. Home
  2. FOXX vs HOTH Comparison

FOXX vs HOTH Comparison

Compare FOXX & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Foxx Development Holdings Inc.

FOXX

Foxx Development Holdings Inc.

HOLD

Current Price

$5.10

Market Cap

16.9M

Sector

N/A

ML Signal

HOLD

Logo Hoth Therapeutics Inc.

HOTH

Hoth Therapeutics Inc.

HOLD

Current Price

$1.08

Market Cap

18.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOXX
HOTH
Founded
2017
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.9M
18.0M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
FOXX
HOTH
Price
$5.10
$1.08
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.50
AVG Volume (30 Days)
3.0M
131.5K
Earning Date
11-18-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$63,030,415.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
139.29
N/A
52 Week Low
$1.71
$0.66
52 Week High
$11.00
$3.80

Technical Indicators

Market Signals
Indicator
FOXX
HOTH
Relative Strength Index (RSI) 51.79 40.47
Support Level $3.67 $1.03
Resistance Level $5.38 $1.12
Average True Range (ATR) 1.01 0.06
MACD -0.04 -0.00
Stochastic Oscillator 33.43 27.08

Price Performance

Historical Comparison
FOXX
HOTH

About FOXX Foxx Development Holdings Inc.

Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals.

About HOTH Hoth Therapeutics Inc.

Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).

Share on Social Networks: